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OBJECTIVE—To determine altered gene expression proﬁles in
subcutaneous adipose and skeletal muscle from nondiabetic,
insulin-resistant individuals compared with insulin-sensitive indi-
viduals matched for BMI.
RESEARCH DESIGN AND METHODS—A total of 62 non-
diabetic individuals were chosen for extremes of insulin sensi-
tivity (31 insulin-resistant and 31 insulin-sensitive subjects; 40
were European American and 22 were African American) and
matched for age and obesity measures. Global gene expression
proﬁles were determined and compared between ethnic groups
and between insulin-resistant and insulin-sensitive participants
individually and using gene-set enrichment analysis.
RESULTS—African American and European American subjects
differed in 58 muscle and 140 adipose genes, including many
inﬂammatory and metabolically important genes. Peroxisome
proliferator–activated receptor g cofactor 1A (PPARGC1A) was
1.75-fold reduced with insulin resistance in muscle, and fatty acid
and lipid metabolism and oxidoreductase activity also were down-
regulated. Unexpected categories included ubiquitination, citrulli-
nation, and protein degradation. In adipose, highly represented
categories included lipid and fatty acid metabolism, insulin action,
and cell-cycle regulation. Inﬂammatory genes were increased in
European American subjects and were among the top Kyoto En-
cyclopedia of Genes and Genomes pathways on gene-set enrich-
ment analysis. FADS1, VEGFA, PTPN3, KLF15, PER3, STEAP4,
and AGTR1 were among genes expressed differentially in both
adipose and muscle.
CONCLUSIONS—Adipose tissue gene expression showed more
differences between insulin-resistant versus insulin-sensitive
groups than the expression of genes in muscle. We conﬁrm the
role of PPARGC1A in muscle and show some support for inﬂam-
mation in adipose from European American subjects but ﬁnd
prominent roles for lipid metabolism in insulin sensitivity inde-
pendent of obesity in both tissues. Diabetes 60:1019–1029, 2011
T
he international obesity epidemic has been ac-
companied by a rapidly increasing prevalence of
type 2 diabetes across ethnic groups (1). The
connection between obesity and impaired glu-
cose homeostasis is indisputable. Nonetheless, the means
by which excessive adiposity induces insulin resistance
and glucose intolerance remain controversial. Indeed, al-
though obesity, insulin resistance, metabolic syndrome,
and glucose intolerance are highly correlated, most obese
individuals do not develop type 2 diabetes, and many
obese individuals have entirely normal metabolic proﬁles
(2,3). In contrast, lean individuals may be as insulin re-
sistant as those with type 2 diabetes (4). Among the mech-
anisms proposed for these paradoxical observations are
muscle-centered hypotheses, including impaired muscle
glucose transport, impaired muscle mitochondrial num-
bers or function, and impaired muscle lipid oxidation (5–7).
Alternatively, adipose-centered hypotheses have included
inﬂammation (1), oxidative stress (8), endoplasmic re-
ticulum stress (9), impaired adipose lipid metabolism
with ectopic lipid deposition (10), and impaired adipo-
genesis (11).
Gene expression studies of adipose and muscle may il-
luminate the physiologic mechanisms that result in insulin
resistance, particularly when these studies are unbiased
and use global transcript proﬁles. Two previous studies
(12,13) of skeletal muscle that compared diabetic or insulin-
resistant and control individuals reported only modest
changes in individual transcript levels. Both studies pro-
posed general alterations in genes involved in oxidative
metabolism and under the control of the transcription fac-
tor peroxisome proliferator–activated receptor (PPAR) g
coactivator (PGC)-1a, encoded by the gene PPARG coac-
tivator 1 (PPARGC1). Some, but not all, subsequent studies
(14,15) support these ﬁndings. Studies of adipose tissue
have been less consistent. In a recent study (16), 70% of
subcutaneous adipose transcripts were correlated with
BMI. Because obesity measures, including BMI, also are
well correlated with altered glucose homeostasis and
whole-body insulin action, distinguishing the molecular
changes in subcutaneous adipose that accompany exces-
sive adiposity from those that cause insulin resistance is
as i g n i ﬁcant challenge. For example, in a recent study (9),
we found that endoplasmic reticulum stress response was
highly correlated with all measures of obesity but was not
independently associated with measures of insulin sensi-
tivity (SI).
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ORIGINAL ARTICLEWith these considerations, we sought an experimental
design that would determine the global transcript proﬁles
of subcutaneous adipose and skeletal muscle in insulin-
resistant and insulin-sensitive, nondiabetic individuals
independent of the confounding effects of obesity. To ac-
complish this goal, we selected individuals at the tails of
the distribution of SI after adjusting for age, sex, and BMI
from a group of 167 study subjects for whom we had both
adipose and muscle samples and a direct measure of SI.
The resulting insulin-resistant and insulin-sensitive groups
were successfully matched for age, sex, and BMI and in-
cluded 40 European American and 22 African American
individuals to examine potential ethnic differences in gene
expression. Genome-wide expression analysis used in this
study allowed us an unbiased hypothesis-free analysis of our
data. However, based on available literature, we also tested
three speciﬁc hypotheses: 1) muscle transcripts downstream
of PPARGC1 (encoding PGC1a) would be reduced in in-
sulin-resistant compared with insulin-sensitive individuals,
2) adipose would show markers of inﬂammation indepen-
dent of obesity, and 3) a subset of metabolically important
genes will be differentially expressed between African
American and European American populations.
RESEARCH DESIGN AND METHODS
Individuals were chosen from previous studies for availability of both adipose
and muscle biopsy samples and SI calculated from the insulin-modiﬁed, in-
travenous glucose tolerance test as described previously (9). In addition,
individuals who were selected were aged 20–55 years and had a BMI between
19 and 42 kg/m
2. From 184 total study participants, 167 individuals (122 Eu-
ropean American and 45 African American) met the inclusion criteria. Indi-
viduals were ranked by SI after adjustment for age, sex, and natural logarithm
of BMI for each ethnic group separately. We ﬁnally selected 62 individuals for
our genome-wide expression analysis, which included 31 individuals (20 Eu-
ropean American and 11 African American) from each tail (insulin resistant
and insulin sensitive; European American and African American subjects were
ranked separately) of the distribution of the standardized residual of SI.
Characteristics of the study sample are shown in Table 1 and Supplementary
Fig. 1. All biopsies were obtained in the fasting state, either before the in-
travenous glucose tolerance test or on a different day. Adipose biopsies were
obtained under local anesthesia from abdominal subcutaneous fat by either
needle biopsy or by incision, rinsed in saline, and frozen in liquid nitrogen. All
muscle samples were obtained from the vastus lateralis by Bergstrom needle
biopsy under local anesthesia and frozen in liquid nitrogen. All study partic-
ipants provided written, informed consent under protocols originally approved
by the University of Arkansas for Medical Sciences.
RNA extraction. Total RNA was isolated from adipose using the RNAeasy
Lipid Tissue Mini kit (Qiagen, Valencia, CA) and from muscle using the
Ultraspec RNA kit (Biotecx Laboratories, Houston, TX). The quantity and
quality of the isolated RNA were determined by ultraviolet spectrophotometry
and electrophoresis using an Agilent 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA), respectively. High-quality RNA with an average RIN (RNA
integrity number) of 8.5 and 8.1, respectively, from adipose and muscle was
used for genome-wide transcriptome analysis.
Microarray studies. Genome-wide transcriptome analysis and initial array
processing was performed by GenUs Biosystems (Northbrook, IL) using
Human Whole Genome 4 3 44 k arrays (Agilent Technologies), according to
vendor-recommended standard protocol.
Data analysis. Processed arrays were analyzed using the nonparametric Wil-
coxon statistic on normalizeddata in Statistical Analysis for Microarraysoftware
(17). Functional annotation of differentially expressed genes were performed by
singular enrichment analysis (SEA) and modular enrichment analysis (MEA)
using the DAVID version 6.7 functional annotation tool (18,19). We also per-
formed canonical pathway analysis and interaction network analysis for these
differentially expressed genes using ingenuity pathway analysis (IPA; version
8.7, available at https://analysis.ingenuity.com). A small number of genes
showed a mean 1.5-fold differential expression; thus, we used all probes cor-
responding to transcripts with the National Center for Biotechnology In-
formation/Entrez identiﬁers irrespective of fold change for gene-set enrichment
analysis (GSEA). The GSEA analysis was performed by GeneTrail (20). A more
detailed description of our microarray studies and data analysis methods is
presented in the Supplementary Data.
RESULTS
Study subjects. The study populations were well matched
on BMI, age, sex, and percentage of fat (Table 1). Con-
sistent with the study design, all measures of insulin sen-
sitivity, including fasting insulin, SI, and compensatory
insulin response (insulin area under curve from an oral
glucose tolerance test, acute insulin response to glucose
[AIRG]) were signiﬁcantly different (P , 0.00001) between
the insulin-resistant and insulin-sensitive groups. Consis-
tent with previous reports (21), disposition index (AIRG 3
SI) in insulin-resistant individuals (Table 1) showed in-
complete compensation. As expected with metabolic
syndrome, insulin-resistant subjects had increased waist-
to-hip ratios (WHRs) and triglyceride levels, which were
statistically signiﬁcant in the European American subset,
and elevated fasting and 2-h postchallenge glucose in both
European American and the combined populations (P ,
0.01 in both for 2-h glucose). Hence, the goals of selecting
age-, sex-, and BMI-matched subjects discordant for SI was
achieved (Supplementary Fig. 1). Salient ethnicity-speciﬁc
differences also were noticed in our cohort; insulin-resistant
individuals of the European American subset showed higher
serum triglyceride levels and lower AIRG compared with the
African American subset, as has been described previously
(21,22).
Ethnic differences in expression proﬁles. Of 41,000
probes available on the Agilent arrays, 30,632 probes were
present in African American adipose samples and 30,020
European American adipose samples. In muscle, we ob-
served 26,314 probes expressed in African American and
23,008 in European American samples. Table 2 summa-
rizes the upregulated and downregulated genes for all
comparisons in the study. In muscle, 58 genes showed
more than a 1.5-fold (African American/European American)
differential expression for at least one probe (Supplementary
Table 1), including metabolically important genes such as
mitogen-activated protein (MAP) 3 kinase 15 (MAP3K15),
24-dehydrocholesterol reductase (DHCR24), and ceramide
kinase (CERK).
In adipose, 140 known genes were differentially ex-
pressed (Supplementary Table 2), again including many
with potential metabolic impact, including vanin1 (VNN1),
hydroxysteroid 11-b dehydrogenase 1 (HSD11B1), glyc-
erol kinase 5 (GK5), stearoyl-CoA desaturase 5 (SCD5),
interleukin 12 receptor, and b 2( IL12RB2). At a 1.5-fold
difference (q value ,5%), six known genes were differen-
tially expressed (African American/European American) in
both muscle and adipose, suggesting likely genetic control.
These genes included CRYBB2, GSTT2, IL27, LRRC36,
MAPK8IP1, and SOS1. Notably, MAPK8IP1 is very near
a chromosome 11 locus that was recently associated with
fasting glucose (23).
Insulin-sensitive versus insulin-resistant expression
proﬁles in muscle. Given the 0.2–0.4% of all transcripts
that differed signiﬁcantly between African American and
European American adipose and muscle samples, we focused
our primary comparison of insulin-resistant and insulin-
sensitive individuals on the combined set (31 insulin-resistant
and 31 insulin-sensitive individuals) after including African
American and European American samples in a separate
permutation group. Among 10 genes that differed between all
insulin-resistant and insulin-sensitive individuals were
PPARG coactivator 1A (PPARGC1A), which has been
reported previously (12,24,25), fatty acid desaturase 1
(FADS1), hyaluronoglucosaminidase 4, Harvey rat sar-
coma viral oncogene (HRAS)-like suppressor 2, proline
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(Table 3), none of which showed signiﬁcant ethnic differ-
ences. Notably, single nucleotide polymorphisms (SNPs)
near FADS have been associated with fasting glucose,
homeostasis model assessment of b-cell function (23), and
plasma phospholipids (26). For comparison with previous
studies, we performed a secondary analysis of the Euro-
pean American subset (20 insulin-resistant and 20 insulin-
sensitive subjects) (Table 2). In the European American
subset, 22 transcripts differed, again including PPARGC1A
(Supplementary Table 3) with a 1.75-fold reduction in in-
sulin-resistant individuals (single point P = 7.5 3 10
25).
Additional transcripts in the European American sample
included serpin peptidase inhibitor A5 (3.37-fold increase
in insulin resistance), cortexin 3 (2.4-fold increase in in-
sulin resistance), glycerol-3-phosphate dehydrogenase 1
(GPD1), sorting nexin-associated golgi protein 1 (SNX18/
SNAG1), and sortilin-related VPS10 domain containing
receptor 1 (SORCS1). Thus, consistent with previous ob-
servations (12), few transcripts exceeded 1.5-fold enrich-
ment, although more transcripts differed in the smaller
subset of European American samples.
Insulin-sensitive versus insulin-resistant expression
proﬁles in adipose. With European American and African
American individuals considered together, 172 genes were
$1.5-fold differentially expressed in subcutaneous adipose
for at least one probe (Tables 2 and 4; Supplementary
Table 4). Annotation of these top differentially expressed
genes using DAVID enrichment analysis indicated over-
representation of these genes in important functional cat-
egories (Supplementary Table 5). Highly represented
categories (Table 4) included lipid/fatty acid/sterol metab-
olism (11 genes including fatty acid synthase, fatty acid
desaturase 1, fatty acid elongase ELOVL5,1 7b hydroxyste-
roid dehydrogenase, acyl-CoA synthase, acetyl CoA carbox-
ylase A, and apolipoprotein B), insulin action and glucose
metabolism (including hexokinase 2, phosphoenolpyruvate
carboxykinase 1, glucose transporters SLC2A3, SLC2A4,
and phosphofructokinase PFKFB3), angiogenesis (includ-
ing vascular endothelial growth factor A [VEGFA], teno-
modulin, and prokinectin1), and cell-cycle regulation and
cell division (including CCND2, CCNB2, CDKN1B,a n d
CAPRIN1). Among genes recently implicated in adipo-
genesis or insulin resistance of obesity, we found reduc-
tions in STEAP4 (27), KLF15 (28), and bone morphogenic
protein BMP7 (29). Notably, missing from the list (Table 4
and Supplementary Table 4) of $1.5-fold differentially
expressed genes were genes implicated in endoplasmic
reticulum stress response, classic inﬂammatory markers
including TNFa, adipokine genes, or macrophage markers.
Female subjects were overrepresented in our study, but
both the insulin-resistant and insulin-sensitive group had a
similar distribution of male and female subjects. However,
our sample set is not sufﬁciently powered to study differ-
ential expression between insulin-resistant and insulin-
sensitive individuals after stratifying for both sex and
ethnicity.
In the European American subset, 149 transcripts for
known genes were increased ($1.5-fold) and 172 were
decreased in adipose from insulin-resistant individuals
(Supplementary Table 6). Many genes involved in immune
response were increased, including transcripts from the
interleukin, immunoglobulin, interferon, chemokine, and
tumor necrosis factor families (Supplementary Table 6).
Among the other genes signiﬁcantly increased in European
American insulin-resistant adipose were resistin (RETN)
(30), thrombospondin 1 (THBS1) (31), sphingosine kinase
1( SPHK1), and cholesterol 25-hydroxylase. Genes reduced
in European American insulin-resistant tissue included
acyl-CoA dehydrogenases ACADL and ACADM, isovaleryl
CoA dehydrogenase, insulin receptor substrate 1 (IRS1),
endoplasmic reticulum stress gene SERP1, acetyl-CoA
carboxylase genes ACACA and ACACB, and acetyl-CoA
synthetase short-chain family member ACSS2. Notably,
genes IRS1 and FADS1 are near SNPs associated with
either type 2 diabetes or fasting glucose (23,32). Reduced
expression of fatty acid metabolism genes among top differ-
entially expressed genes was again prominent by DAVID
analysis and additionally showed enrichment of genes
related to immune response in the European American
subset (Supplementary Table 7). Ingenuity pathway anal-
ysis (IPA) of genes differentially expressed in European
American insulin-resistant and insulin-sensitive individuals
in adipose showed propionate metabolism as the most
signiﬁcant canonical pathway with seven genes (ACADL,
ACACB, ACSS2, ACACA, EHHADH, IVD,a n dACADM)
differentially expressed ($1.5-fold) in this pathway
(Supplementary Table 8). Interaction network analysis using
IPA, however, showed a network of genes related to im-
mune response (score = 42, with 25 differentially expressed
genes) and a network related to inﬂammatory response
(score = 37, with 24 differentially expressed genes) as most
signiﬁcant (Supplementary Fig. 2).
GSEA. A previous study of muscle found that most tran-
scripts showed modest (,1.5-fold) expression changes
but were clustered in biological pathways (12). To identify
altered biological pathways, we performed GSEA using
GeneTrail (33). GSEA considers all expressed genes by
rank without a fold-change threshold and thus may iden-
tify altered pathways in which no individual members are
TABLE 2
Summary of differentially expressed genes for all comparisons
Comparison n Tissue Upregulated genes* Downregulated genes*
African American/European American 22/40 Muscle 22 36
African American/European American 22/40 Adipose 23 117
Insulin-resistant/insulin-sensitive, all 31/31 Muscle 3 7
Insulin-resistant/insulin-sensitive, European American 20/20 Muscle 17 5
Insulin-resistant/insulin-sensitive, all 31/31 Adipose 38 134
Insulin-resistant/insulin-sensitive, European American 20/20 Adipose 149 172
*Number of genes that met the criteria of q value ,5%, fold change either .1.50 (upregulated), or ,0.667 (downregulated) and single-point P
value from t test of ,0.05 for at least one expressed probe. Genes with probes for multiple transcripts are considered signiﬁcant only when all
expressed probes are in same direction. The table includes genes with corresponding Entrez ID numbers but not referring to open reading
frames, transcripts of unknown function, or pseudogenes. n, number of samples in each subset.
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1022 DIABETES, VOL. 60, MARCH 2011 diabetes.diabetesjournals.orgaltered by 1.5-fold. We focused primarily on the full data-
set but, for comparability with previous studies, also per-
formed analyses using only European American samples.
In muscle, GSEA of all samples showed downregulation
of Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways for arginine and proline metabolism, calcium
signaling, MAPK and VEGF signaling, inositol phosphate
metabolism, and PPAR signaling in the insulin-resistant
group, whereas gene ontology classes were remarkable for
downregulation of lipid and fatty acid metabolism, car-
boxylic acid and oxoacid metabolism, regulation of oxido-
reductase activity, insulin receptor signaling, and glucose/
hexose/monosaccharide transport (Supplementary Table 9).
European American samples were similar but showed no
prominent role for KEGG pathways or gene ontology terms
related to oxidative phosphorylation (data not shown).
Unexpectedly, categories related to ubiquitin-protein ligase,
ubiquitin cycles, and apoptosis were prominent.
GSEA in subcutaneous adipose identiﬁed primary up-
regulated KEGG pathways for complement and comple-
ment cascades, antigen processing and presentation, and
natural killer cell–mediated cytotoxicity; top-ranked gene
ontology terms likewise supported upregulation of in-
ﬂammatory pathways related to chemokines, antigen pro-
cessing, immune response, and inﬂammatory response in
the insulin-resistant group (Supplementary Table 10).
Prominent downregulated KEGG pathways in insulin-
resistant individuals included propanoate and butanoate
metabolism, valine/leucine/isoleucine degradation, tricar-
boxylic acid cycle, fatty acid metabolism, steroid biosyn-
thesis, insulin signaling pathway, and PPAR signaling
pathway. Gene ontology terms provided a similar picture,
with terms related to lipid, fatty acid and steroid metabo-
lism all downregulated (Supplementary Table 10). Signiﬁ-
cant enrichment of the PPAR signaling pathway among
genes downregulated in insulin-resistant individuals was
consistent with the downregulation of several lipid and
carbohydrate metabolism genes including glycogen syn-
thase 2 (GYS2) in adipose of insulin-resistant subjects.
GYS-2 is the rate-limiting enzyme in the storage of glyco-
gen in both liver and adipose tissue and is regulated via
a PPAR response element present in the ﬁrst intron (34).
Overall, conclusions were similar in the European Ameri-
can subset, although more categories including adipo-
cytokine signaling and transforming growth factor b signaling
pathway were present (Supplementary Table 11).
Transcripts differentially expressed in adipose and
muscle. A unique aspect of our study was the availability
of both adipose and muscle. Transcripts concordantly
regulated in adipose and muscle may provide a stronger
indication of underlying pathophysiology. Considering
only $1.5-fold differentially expressed genes in all indi-
viduals, only FADS1 shows downregulation in both adi-
pose and muscle of insulin-resistant individuals. We thus
tested all samples for concordantly regulated transcripts
with at least a 1.25-fold change, a q value ,10%, and a
nominally signiﬁcant P value in both tissues (Supplementary
Table 12). We identiﬁed 14 genes concordantly increased in
insulin-resistant subjects, including desert hedgehog homo-
log (DHH), serpin peptidase inhibitor SERPINA5, calcium
binding proteins S100A4 and S100A6, kinensin family
member 1B, and activating transcription factor 5. Among 55
genes with reduced expression, in insulin-resistant samples
were cell cycle protein CAPRIN1, endoplasmic reticulum
stress–related protein SERP1, angiotensin II receptor
(AGTR1), STEAP4, protein tyrosine phosphatase PTPN3,
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PER3, MAPK MAPK14, and possible vesicle transport
protein archain 1 (ARCN1). Also among the genes con-
cordantly downregulated in insulin-resistant subjects were
fatty acid desaturase (FADS1), VEGFA, and CDKAL1, all
of which were implicated by association of nearby SNPs
with type 2 diabetes (35) or fasting glucose (23).
Replication of expression signals in adipose. We se-
lected 17 transcripts to test using real-time PCR compared
with 18S RNA. Most transcripts were selected for a known
role in glucose homeostasis or adipocyte growth, but we
included S100A1, which has no known role. Primers were
designed as close to array primers as possible. Adequate
cDNA was not available for four European American
and two African American samples. Nonetheless, 12 of 17
transcripts showed signiﬁcant differences either in all
samples or the European American or African American
subset. Another three of 17 transcripts demonstrated a
trend of signiﬁcant association (INPPA, P = 0.09; ACACA,
P = 0.09; and VEGFA, P = 0.08) in the European American
subset. The direction of differential expression was the
same as the array with all but S100A1 (Supplementary
Table 13). In general, the ratios from real-time PCR were
less than those observed in the arrays. Among the reasons
for the more modest observations with RT-PCR were dif-
ﬁculty in matching array probe locations and likely splice
variants and use of different normalization standards.
Nonetheless, most ﬁndings served to validate array signals.
DISCUSSION
Obesity is highly correlated with insulin resistance, but
both insulin-resistant lean individuals and metabolically
healthy obese individuals are well recognized. A recent
study (16) also showed a high correlation between expres-
sions of a large number of transcripts in subcutaneous
adipose with BMI. Thus, in most published studies the
search for insulin sensitivity–mediated changes in adipose
tissue gene expression was confounded by BMI. In addi-
tion, many published investigations compared subjects
with overt type 2 diabetes, where gene expression may
have been altered by hyperglycemia, to normal control
subjects. Gene expression in some previous studies was
inﬂuenced by obtaining muscle biopsies during the hyper-
insulinemic state at the end of a 2-h euglycemic clamp
(12). To examine the role of adipose and muscle gene
expression while minimizing the confounders, we matched
nondiabetic individuals who were at extremes of insulin
sensitivity for BMI and obesity measures and obtained
both adipose and muscle biopsies during a fasting state.
Additional unique features of the current study were the
inclusion of participants of both European and African
ancestry, the inclusion of both adipose and muscle tissue
from the same individuals, and the relatively large sample size
of our study compared with many earlier studies (12,13,36).
These features, along with different arrays and probe sets,
likely explain the differences between the current study and
other reports.
Several conclusions are evident from our study. First,
considerably more transcripts differ with SI in adipose
than in muscle tissue, which may suggest a more important
role for altered adipocyte transcription in impaired insulin
action. Second, although only a small number of tran-
scripts differed signiﬁcantly between European American
and African American participants, many of these tran-
scripts were in pathways likely to contribute to metabolic
differences including phospholipases, immune factors, and
fatty acid and ceramide metabolism. Using stringent cri-
teria, only six genes with putative metabolic importance
(CLIC6, HSD11B1, SERPINA3, THBS1, TMEM135,a n d
TNMD) showed ethnic difference as well as differential ex-
pression in adipose of insulin-resistant individuals. However,
using less stringent criteria (single-point P , 0.05 for Af-
rican Americans/European Americans, irrespective of q
value), nearly 20% of adipocyte transcripts that were as-
sociated with SI in European American participants also
differed between European American and African Ameri-
can samples. A recent study of lymphocytes suggested that
levels of key glucose homeostasis transcripts downstream
of SREBP1 differed between European American and Af-
rican American individuals (37). These expression differ-
ences may reﬂect phenotypic differences in insulin action,
secretion, and clearance between European American and
African American individuals (21,22). Although the African
American subset in our study was of a size comparable to
previous studies of global transcript levels, a larger study
comparing expression patterns in African American and
European American individuals matched for obesity
measures is needed to determine whether apparent tran-
script differences result from a combination of small
sample size and additional variability and heterogeneity in
the African American subset. For example, we observed
more differentially expressed transcripts in the smaller
European American population than in the full sample set.
This may be a result of a type I statistical error; however,
an alternative explanation for this paradox is that African
American samples introduced heterogeneity and increased
the variance, and, thus, fewer transcripts reached signiﬁ-
cance. In our analysis, comparison between all insulin-
resistant and insulin-sensitive individuals were performed
after considering African American and European Ameri-
can individuals as separate permutation groups to minimize
that error. Differences reported in European American in-
sulin-resistant groups compared with European Ameri-
can insulin-sensitive group sc o u l da l s ob ee x p l a i n e db y
increased visceral fat (indicated by WHR) in European
American insulin-resistant groups.
Previous studies in muscle have argued for a key role
of oxidative phosphorylation (OXPHOS) (12,13). We also
found that PPARGC1A (PGC1a) was reduced in insulin-
resistant muscle, but of 17 OXPHOS genes that were re-
ported previously, we found nominal evidence (P , 0.05) of
differential expression in only four genes (NDUFB5, SDHD,
UCRC,a n dNDUFU2), and for all of these, gene expression
increased ~1.2-fold in insulin-resistant muscle, arguing
against decreased mitochondrial oxidation in insulin
resistance. This conclusion was supported by GSEAs, which
failed to identify either KEGG pathways or gene ontology
terms related to oxidative phosphorylation. Instead, in ad-
dition to PPAR signaling, we found downregulation of
pathways for arginine and proline metabolism, lipid and
fatty acid metabolism, and hexose transport. Novel ﬁndings
included differential expression of genes in categories of
ubiquitin-protein ligase and apoptosis.
In addition to inﬂammatory markers, a large number of
genes in adipose are reported to be associated with insulin
resistance in humans. In agreement with our previous
studies (9), we found no evidence for clustering with in-
sulin sensitivity for 240 transcripts related to endoplasmic
reticulum stress. We reviewed the literature and identiﬁed
104 transcripts not related to endoplasmic reticulum stress
that were reported as associated with insulin resistance
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the same direction as previously reported and found sup-
port for 50 of these transcripts, many falling into pathways
identiﬁed in our global analysis. In the analysis of all
subjects, genes involved in inﬂammation were missing
from the list of 1.5-fold differentially expressed genes be-
tween the adipose of insulin-resistant and insulin-sensitive
subjects. However, GSEA of all subject data and analysis
of the European American subset indicated the differential
expression of genes in inﬂammatory pathways. Inﬂamma-
tion was supported with upregulation of CCL2, CCL3,
CD68, IL6, IL6R, MSR1, RETN, SPP1, and TNF. This re-
sult is consistent with a recent ﬁnding from Hyatt et al.,
which showed signiﬁcantly lower inﬂammation in African
American individuals compared with BMI-matched Euro-
pean American individuals (47). Thus, our study, along
with published studies, indicates an important ethnic dif-
ference in the pathophysiology of insulin resistance (34).
The recently described (48) gene SPARC (osteonectin)
was modestly increased with insulin resistance (1.2-fold, q
value ,5%). In contrast to our ﬁndings in muscle, we found
changes in oxidative phosphorylation, with genes
NDUFS1, NDUFB5, and NRF1 modestly (1.2-fold) down-
regulated with insulin resistance. Transcription factors
PPARG, PPARA, CEBPA, and CEBPB were all modestly
downregulated, as were insulin signaling genes SLC2A4
(GLUT4), IRS1, MAP4K4, and HK2. However, as we noted
above, alterations in lipid metabolic genes in adipose tis-
sue were most prominent with the downregulation of SCD
(49), FADS1, and FASN with insulin resistance (50). In
addition to PPARA, we found downregulation of LIPIN1 in
adipose tissue of insulin-resistant compared with insulin-
sensitive subjects (51). Finally, in contrast to published
ﬁndings (52), we found that APP was 1.2-fold down-
regulated rather than upregulated with insulin resistance.
Thus, we suggest that many proposed associations were
the result of obesity rather than primarily associated with
insulin resistance.
By testing adipose and muscle in the same individuals at
extremes of insulin sensitivity, we were able to identify
pathways unique to each tissue but also similar mecha-
nisms in adipose and muscle. We identiﬁed 69 genes with
concordant expression in insulin-resistant muscle and ad-
ipose, of which only 14 genes were increased with insulin
resistance. Although many of the 69 concordantly re-
gulated transcripts have no obvious roles in adipose or
muscle, genes associated with cell-cycle progression and
differentiation are well represented. Concordantly upreg-
ulated genes S100A4 and S100A6 encode calcium binding
proteins that are involved in cell-cycle progression and cell
differentiation, ATF5 interacts with cell cycle genes, and
downregulated gene PPFIBP1 interacts with S100A4.
Other concordantly downregulated genes with cell-cycle
roles include CDKAL1. Interestingly, both S100A4 and
S100A6 reside near the well-replicated 1q21 region of type
2 diabetes linkage, whereas CDKAL1 is a well replicated
type 2 diabetes gene based on genome-wide association
scans (53). Several additional genes are involved in trans-
lation initiation, including helicase gene DDX42, initiation
factor EIF4B, and CAPRIN1. Also among the concordantly
regulated genes were four histone members (increased in
insulin resistance) and the chromatin binding factor,
transcriptional regulator, and part of the histone deacety-
lase complex CTCF. These ﬁndings suggest a prominent
role for chromatin modiﬁcation, translation initiation, and
cell-cycle regulation in insulin resistance.
A number of coordinately regulated genes are involved
in cellular stress responses, inﬂammatory pathways, and
unfolded protein response including BCL2A1, CEBPB,
MAPK14, SERP1, SMG1, STEAP4, and VCP. It was sur-
prising that these genes are concordantly expressed in
muscle, but it is consistent with a recent description (54)
of increased macrophages in insulin resistant muscle. Fi-
nally, fatty acid metabolism was prominent in both tissues,
with reduced expression in insulin-resistant individuals
for ACAD10, FADS1, and CYP4V2. Other interesting con-
cordantly downregulated transcripts include PER3, a gene
associated with circadian rhythm but of unknown function
in adipose and muscle; AGTR1 encoding the angiotensin 2
receptor; and genes KLF15 and CEBPB, encoding tran-
scription factors primarily known for adipose function. Like
CDKAL1,g e n e sVEGFA and FADS1 are near well-replicated
SNPs associated with type 2 diabetes or fasting glucose
(23,35).
The current study included a larger sample than most
previous studies, included a biethnic population, and, as
noted above, provided the opportunity to compare adipose
and muscle in individuals matched for BMI but were dis-
cordant for insulin sensitivity. Nonetheless, this cross-
sectional study has some limitations. Although larger than
most earlier reports, the design of this study was inevitably
of limited size relative to studies focused on mapping ge-
netic etiology. Although inclusion of an African American
population provided a unique opportunity to deﬁne differ-
ences among ethnic groups, this population may have added
heterogeneity. A cross-sectional study cannot deﬁne cause
and effect; thus, in common with previous studies we cannot
exclude the possibility that some of the differences in ex-
pression were the result of impaired insulin action rather
than the cause. Insulin signaling affects many downstream
networks. In this study, the observed direction of changes of
differentially expressed genes in carbohydrate metabolism,
cell-cycle regulation, lipid metabolism, and arginine-proline
metabolism are consistent with the known functional effect
of reduced insulin signaling in insulin-resistant individuals.
However, some other differences between insulin-resistant
and insulin-sensitive subjects, including the increase in in-
ﬂammation and reduction in angiogenesis, are less readily
explained by altered insulin signaling.
In summary, by comparing BMI-matched individuals at
extremes of insulin sensitivity, we show that expression
changes are more prominent in adipose than muscle, con-
ﬁrming earlier and smaller array studies of muscle, but we
conﬁr mt h er o l ef o rPPARGC1A (encoding PGC1) in muscle.
Although we indeed found the expected role for inﬂamma-
tion in adipose, the most highly differentially expressed genes
suggest a prominent role for pathways involved in fatty acid
metabolism and cell-cycle regulation in both adipose and
muscle. Although signiﬁcant differences observed between
African American and European American individuals did
not overlap with the signiﬁcant differences observed be-
tween insulin-resistant and insulin-sensitive individuals,
ethnic differences between metabolically important genes
were prominent and deserve further study.
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